This is the text extract for Proposal for radiological contrast media. Closed, browse documents here.

30 July 2010

Proposal for radiological contrast media

PHARMAC is seeking feedback on a proposal to list in Part II of Section H of the Pharmaceutical Schedule, or amend the listing of, a number of radiological contrast media as part of a provisional agreement with Regional Health Limited. In summary, this proposal would result in: § listing of CTPlus, a brand of barium sulphate oral suspension from 1 September 2010; and ongoing listings for Multihance and Ioscan, with a small price increase for Ioscan from 1 September 2010.

§

Feedback sought PHARMAC welcomes feedback on this proposal. To provide feedback, please submit it in writing by Thursday, 12 August 2010 to: Andrew Davies Procurement Initiatives Manager PHARMAC PO Box 10 254 Wellington 6143 Email: andrew.davies@pharmac.govt.nz Fax: 04 460 4995

All feedback received before the closing date will be considered by PHARMAC’s Board (or Chief Executive acting under delegated authority) prior to making a decision on this proposal. Details of the proposal The following listings would be effective in Part II of Section H of the Pharmaceutical Schedule from 1 September 2010:

Chemical Gadobendate dimeglumine Gadobendate dimeglumine Sodium diotrizoate Barium sulphate Barium sulphate Presentation Solution for injection, 0.5 g per L, 10 mL Solution for injection, 0.5 g per L, 20 mL Oral solution, 3.705 g per 10 mL sachet Oral suspension, 2.2%, 250 mL bottle Oral suspension, 2.2%, 450 mL bottle Brand MultiHance MultiHance Ioscan CT Plus+ CT Plus+ Pack size 10 10 50 24 24 Price $324.74 $636.28 $156.12 $175.00 $220.00

A371053 - T09-391

None of the products would have Hospital Supply Status, but they would be protected from delisting until 30 June 2012, meaning no other supplier could gain Hospital Supply Status for these product categories in this time.

A371053T09-391

Page 2 of 2